文献速递泌尿生殖腹部MRUS

尿液生物标志物风险评分与多参数MRI在活检初治患者中检测临床显著前列腺癌的价值

Usefulness of urinary biomarker-based risk score and multiparametric MRI for clinically significant prostate cancer detection in biopsy-naïve patients.
PubMed 文献 · Abdom Radiol (NY) · 2025-01-25

单中心前瞻性研究纳入208例活检初治男性,比较mpMRI、尿液基因检测(GUT)及PCPTRC2对临床显著前列腺癌的诊断准确性。GUT联合mpMRI的敏感度(99.1%)显著高于GUT(84.4%)和mpMRI(93.8%)单独应用,且该联合方案较mpMRI联合PCPTRC2可避免更多不必要穿刺(25% vs 2.4%)。

要点

  • GUT联合mpMRI对csPCa的敏感度达99.1%,显著高于单独GUT(84.4%)或mpMRI(93.8%)。
  • mpMRI联合PCPTRC2敏感度为99.0%,但仅避免2.4%不必要穿刺,低于mpMRI联合GUT的25%。
  • GUT阳性率为67.8%,PI-RADS≥3占比81.7%。

核心结论

  • GUT与mpMRI联合可在极少漏诊csPCa的前提下避免相当比例的不必要穿刺。

研究设计与样本

  • 单中心前瞻性研究,2021至2024年纳入208例活检初治男性(平均年龄62.9岁±8.2),行前列腺mpMRI、GUT及超声引导下穿刺,并用PCPTRC2计算csPCa风险。

诊断标准与关键数值

  • GUT整合PCA3与TMPRSS2基因及ERG融合基因(T:E)RNA水平、患者年龄及PSA密度;GUT联合mpMRI敏感度99.1%,GUT单独84.4%,mpMRI单独93.8%(p≤0.05);mpMRI联合PCPTRC2敏感度99.0%。

临床应用与阅片要点

  • 作者认为GUT与mpMRI联合可能避免相当比例的不必要穿刺,且漏诊csPCa风险极小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to investigate the accuracy of multiparametric magnetic resonance imaging (mpMRI), genetic urinary test (GUT), and prostate cancer prevention trial risk calculator version 2.0 (PCPTRC2) for the clinically significant prostate cancer (csPCa) diagnostic in biopsy-naïve patients.

MATERIALS AND METHODS: In a single center study between 2021 and 2024 participants underwent prostate mpMRI, GUT, and ultrasound (US) guided biopsy. The csPCa risk was calculated using PCPTRC2. After conducting a digital rectal examination (DRE), a GUT was performed. It incorporated the RNA levels of prostate cancer antigen 3 (PCA3) and transmembrane serine protease 2 (TMPRSS2) gene and ETS-related gene (ERG) fusion genes (T: E), along with the patient's age and PSA density. The McNemar test compared detection rates between modalities.

RESULTS: 208 (mean age 62.9 years +/- 8.2) men were included prospectively. A positive GUT score was found in 67.8% and PIRADS ≥3 in 81.7% of all cases. The combination of GUT with mpMRI showed significantly higher sensitivity (99.1%) than GUT and mpMRI alone, 84.4% and 93.8%, respectively (p ≤ 0.05). Similarly, very high sensitivity (99.0%) was achieved by combining mpMRI with PCPTCR2. Nevertheless, mpMRI plus GUT combination exceeded mpMRI plus PCPTCR2 by allowing to save a higher fraction of unnecessary biopsies, 25% and 2.4%, respectively.

CONCLUSION: GUT and mpMRI combination would allow saving a substantial fraction of unnecessary biopsies with minimal risk of missing csPCa cases.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Kemesiene J, Nicolau C, Cholstauskas G, et al. Usefulness of urinary biomarker-based risk score and multiparametric MRI for clinically significant prostate cancer detection in biopsy-naïve patients. Abdom Radiol (NY). 2025. PMID: 39862284. doi:10.1007/s00261-024-04727-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。